F. Dautzenberg

发表

Regulation of Corticotropin‐Releasing Factor Receptor Function in Human Y‐79 Retinoblastoma Cells: Rapid and Reversible Homologous Desensitization but Prolonged Recovery

R. Hauger, J. Spiess, F. Dautzenberg, 1997, Journal of neurochemistry.

The Concise Guide to Pharmacology 2013/14: Overview

Adam J Pawson, Stephen P. H. Alexander, A. A. Khan, 2013, British journal of pharmacology.

Expression, binding, and signaling properties of CRF2(a) receptors endogenously expressed in human retinoblastoma Y79 cells: passage‐dependent regulation of functional receptors

I. van der Linden, R. Hauger, G. Vauquelin, 2008, Journal of neurochemistry.

GRK3 regulation during CRF- and urocortin-induced CRF1 receptor desensitization.

R. Hauger, S. Braun, F. Dautzenberg, 2002, Biochemical and biophysical research communications.

G-protein-coupled receptor kinase 3- and protein kinase C-mediated desensitization of the PACAP receptor type 1 in human Y-79 retinoblastoma cells

R. Hauger, F. Dautzenberg, 2001, Neuropharmacology.

Molecular Mechanisms of Corticotropin-Releasing Factor Receptor-Induced Calcium Signaling

I. van der Linden, G. Vauquelin, F. Dautzenberg, 2009, Molecular Pharmacology.

CRF-1 Corticotropin-Releasing Factor Receptor

R. Hauger, F. Dautzenberg, 2008 .

Corticotropin‐Releasing Hormone (CRH) Expression and Protein Kinase A Mediated CRH Receptor Signalling in an Immortalized Hypothalamic Cell Line

T. Rizvi, M. Pisarska, G. Aguilera, 2003, Journal of neuroendocrinology.

Molecular cloning and functional expression of the mouse CRF2(a) receptor splice variant

F. Dautzenberg, S. Wille, O. Brauns, 2004, Regulatory Peptides.

Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy

R. Hauger, S. Braun, J. Olivares-Reyes, 2012, Neuropharmacology.

Cloning of a Human Renal p–Aminohippurate Transporter, hROAT1

G. Reid, G. Burckhardt, F. Dautzenberg, 2008, Kidney and Blood Pressure Research.

Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-- an update.

T. Steckler, F. Dautzenberg, 2006, CNS & neurological disorders drug targets.

Regulation of the Stress Response by Corticotropin-Releasing Factor Receptors

R. Hauger, F. Dautzenberg, 2000 .

Stimulation of neuropeptide Y-mediated calcium responses in human SMS-KAN neuroblastoma cells endogenously expressing Y2 receptors by co-expression of chimeric G proteins.

F. Dautzenberg, 2005, Biochemical pharmacology.

Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF1) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism

F. Dautzenberg, S. Wille, 2004, Regulatory Peptides.

CRF1 Receptor Signaling via the ERK1/2-MAP and Akt Kinase Cascades: Roles of Src, EGF Receptor, and PI3-Kinase Mechanisms

R. Hauger, K. Catt, A. M. Fuentes-González, 2019, Front. Endocrinol..

Contribution of melanin-concentrating hormone (MCH1) receptor to thermoregulation and sleep stabilization: Evidence from MCH1 (−/−) mice

T. Steckler, W. Drinkenburg, H. Huysmans, 2011, Behavioural Brain Research.

Molecular Properties of the CRF Receptor

R. Hauger, J. Radulovic, J. Spiess, 1998, Trends in Endocrinology & Metabolism.

International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands

R. Hauger, P. Plotsky, W. Vale, 2003, Pharmacological Reviews.

Urocortin: slower dissociation than corticotropin releasing factor from the CRF binding protein.

Gavin Kilpatrick, S. Henriot, F. Dautzenberg, 1999, European journal of pharmacology.

Design, synthesis and pharmacological characterization of new highly selective CRF2 antagonists: development of 123I-K31440 as a potential SPECT ligand

F. Dautzenberg, A. Rühmann, J. Higelin, 2002, Peptides.

Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.

M. Wright, F. Dautzenberg, G. Huber, 2001, The Journal of pharmacology and experimental therapeutics.

Dephosphorylation of phosphorylated atrial natriuretic peptide by protein phosphatase 2A.

D. Richter, D. Müller, F. Dautzenberg, 1993, European journal of biochemistry.

Molecular biology of the CRH receptors— in the mood

R. Hauger, Gavin Kilpatrick, J. Moreau, 2001, Peptides.

Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity

F. Dautzenberg, B. Zimmermann, O. Brauns, 2002, Peptides.

Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo.

P. Malherbe, Gavin Kilpatrick, C. Kratzeisen, 2001, The Journal of pharmacology and experimental therapeutics.

Corticotropin-releasing factor receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

R. Hauger, T. Steckler, W. Vale, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart.

R. Hauger, F. Dautzenberg, O. Brauns, 2002, Molecular pharmacology.

Evidence for the abundant expression of arginine 185 containing human CRF2α receptors and the role of position 185 for receptor-ligand selectivity

Gavin Kilpatrick, F. Dautzenberg, G. Huber, 2000, Neuropharmacology.

Functional characterization of corticotropin-releasing factor type 1 receptor endogenously expressed in human embryonic kidney 293 cells.

F. Dautzenberg, U. Teichert, J. Higelin, 2000, European journal of pharmacology.

The ligand‐selective Domains of Corticotropin‐Releasing Factor Type 1 and Type 2 Receptor Reside in Different Extracellular Domains

R. Hauger, Gavin Kilpatrick, F. Dautzenberg, 1999, Journal of neurochemistry.

Identification of Amino Acids in the N‐Terminal Domain of Corticotropin‐Releasing Factor Receptor 1 that Are Important Determinants of High‐Affinity Ligand Binding

J. Spiess, F. Dautzenberg, S. Wille, 1999, Journal of neurochemistry.

Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site.

R. Lohmann, J. Spiess, F. Dautzenberg, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Structure-function relationship of different domains of the rat corticotropin-releasing factor receptor.

J. Radulovic, J. Spiess, F. Dautzenberg, 1997, Brain research. Molecular brain research.

Rapid agonist-induced phosphorylation of the human CRF receptor, type 1: a potential mechanism for homologous desensitization.

R. Hauger, K. Catt, S. Braun, 2000, Biochemical and biophysical research communications.

Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist

W. Guba, W. Neidhart, F. Dautzenberg, 2005, Neuropharmacology.

High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.

F. Monsma, G. Adam, A. Cesura, 2000, Journal of medicinal chemistry.

A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.

G. Adam, Gavin Kilpatrick, K. Lundstrom, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Structure-activity relationships of 2-arylamido-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic action.

Claude Ostermann, M. Schaefer, F. Dautzenberg, 2012, Bioorganic & medicinal chemistry letters.

Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties.

G. Adam, M. Hennig, A. Cesura, 2000, European journal of medicinal chemistry.

Novel hexahydrospiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptor agonists.

G. Adam, M. Hennig, A. Cesura, 2003, Journal of medicinal chemistry.

Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists.

Julen Oyarzabal, Trevor Howe, I. van der Linden, 2009, Journal of medicinal chemistry.

MINI-REVIEW Nociceptive and behavioural sensitisation by protein kinase Ce signalling in the CNS

J. Neefs, K. V. Kolen, F. Dautzenberg, 2008 .

Nociceptive and behavioural sensitisation by protein kinase Cɛ signalling in the CNS

J. Neefs, F. Dautzenberg, K. Van Kolen, 2007 .

Synthesis of (1S,3aS)-8- (2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro [4.5]decan-4-one, a Potent and Selective Orphanin FQ (OFQ) Receptor Agonist with Anxiolytic-Like Properties.

G. Adam, M. Hennig, A. Cesura, 2000 .

The CRF peptide family and their receptors: yet more partners discovered.

R. Hauger, F. Dautzenberg, 2002, Trends in pharmacological sciences.

Molecular regulation of the CRF system

N. Kalin, T. Steckler, P. Roseboom, 2005 .

Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment

Christine C. Hudson, R. Hauger, S. Braun, 2013, Regulatory Peptides.

Corticotropin-releasing factor receptors induce calcium mobilization through cross-talk with Gq-coupled receptors.

G. Vauquelin, F. Dautzenberg, E. Gutknecht, 2010, European journal of pharmacology.

CRF-2 Corticotropin-Releasing Factor Receptor

R. Hauger, F. Dautzenberg, 2008 .

Carboxyl-terminal and intracellular loop sites for CRF1 receptor phosphorylation and beta-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses.

Christine C. Hudson, R. Hauger, J. Olivares-Reyes, 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells.

I. van der Linden, R. Hauger, J. Olivares-Reyes, 2004, Biochemical pharmacology.

Mediation of Corticotropin Releasing Factor Type 1 Receptor Phosphorylation and Desensitization by Protein Kinase C: A Possible Role in Stress Adaptation

R. Hauger, K. Catt, S. Braun, 2003, Journal of Pharmacology and Experimental Therapeutics.

Interaction of neuropeptide Y and corticotropin-releasing factor signaling pathways in AR-5 amygdalar cells

R. Hauger, M. Pisarska, W. Chance, 2001, Peptides.

GRK3 mediates desensitization of CRF1 receptors: a potential mechanism regulating stress adaptation.

R. Hauger, S. Braun, F. Dautzenberg, 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

Corticotropin-releasing factor receptor type 1 from Tupaia belangeri--cloning, functional expression and tissue distribution.

E. Fuchs, J. Spiess, F. Dautzenberg, 1998, European journal of biochemistry.

The highly selective CRF2 receptor antagonist K41498 binds to presynaptic CRF2 receptors in rat brain

A. Lawrence, F. Dautzenberg, A. Rühmann, 2002 .

7TM receptors: the splicing on the cake.

R M Eglen, G. Martin, Gavin Kilpatrick, 1999, Trends in pharmacological sciences.

Identification of Two Corticotropin‐Releasing Factor Receptors from Xenopus laevis with High Ligand Selectivity: Unusual Pharmacology of the Type 1 Receptor

J. Spiess, F. Dautzenberg, M. Palchaudhuri, 1997, Journal of neurochemistry.

Corticotropin-releasing factor receptor 1 in mouse spleen: expression after immune stimulation and identification of receptor-bearing cells.

J. Radulovic, J. Spiess, M. Radulovic, 1999, Journal of immunology.

Urocortins of the South African clawed frog, Xenopus laevis: conservation of structure and function in tetrapod evolution.

R. Denver, F. Dautzenberg, E. Crespi, 2005, Endocrinology.

Receptor-Bearing Cells Stimulation and Identification of Mouse Spleen : Expression After Immune Corticotropin-Releasing Factor Receptor 1 in

J. Radulovic, J. Spiess, M. Radulovic, 1999 .

Irreversible Binding Kinetics of Neuropeptide Y Ligands to Y2 but Not to Y1 and Y5 Receptors

F. Dautzenberg, S. Neysari, 2005, Pharmacology.

Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

R. Hauger, V. Risbrough, Richard L Hauger, 2006, CNS & neurological disorders drug targets.

Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling.

J. Spiess, F. Dautzenberg, A. Rühmann, 1996, Proceedings of the National Academy of Sciences of the United States of America.

125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors

F. Dautzenberg, J. Higelin, Cristina Paternoster, 2001, Neuropharmacology.

Nociceptive and behavioural sensitisation by protein kinase Cepsilon signalling in the CNS.

J. Neefs, F. Dautzenberg, K. Van Kolen, 2008, Journal of neurochemistry.

Blocking melanin-concentrating hormone MCH1 receptor affects rat sleep-wake architecture.

T. Steckler, W. Drinkenburg, J. Alcázar, 2008, European journal of pharmacology.

Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture.

H. Geys, T. Steckler, W. Drinkenburg, 2009, European journal of pharmacology.

Corticotropin-releasing factor receptors in GtoPdb v.2023.1

R. Hauger, T. Steckler, W. Vale, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.

A. Lawrence, F. Dautzenberg, A. Rühmann, 2002, British journal of pharmacology.

Role of CRF Receptor Signaling in Stress Vulnerability, Anxiety, and Depression

R. Hauger, J. Olivares-Reyes, V. Risbrough, 2009, Annals of the New York Academy of Sciences.

Therapeutic potential of group III metabotropic glutamate receptors.

H. Lavreysen, F. Dautzenberg, 2008, Current medicinal chemistry.

Pharmacological Characterization of JNJ-40068782, a New Potent, Selective, and Systemically Active Positive Allosteric Modulator of the mGlu2 Receptor and Its Radioligand [3H]JNJ-40068782

A. Megens, X. Langlois, G. Macdonald, 2013, The Journal of Pharmacology and Experimental Therapeutics.

8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists.

G. Adam, A. Cesura, S. Röver, 1999, Bioorganic & medicinal chemistry letters.

Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands.

A. Beck‐Sickinger, M. Lang, F. Dautzenberg, 2004, Journal of medicinal chemistry.

N‐Terminal Splice Variants of the Type I PACAP Receptor: Isolation, Characterization and Ligand Binding/Selectivity Determinants

R. Hauger, F. Dautzenberg, S. Wille, 1999, Journal of neuroendocrinology.